Five-year clinical data for soft volume filler presented at ASAPS annual meeting
San Diego — Medical News Today reports that Danish firm Contura International A/S presented five-year clinical data for its soft volume filler Aquamid at the annual meeting of the American Society of Aesthetic Plastic Surgery (ASAPS), held here recently.
Aquamid is used to rejuvenate or contour the face, either by restoring lost volume or by adding extra volume. Contura is currently conducting a multicenter, comparative clinical trial of Aquamid in the United States.
The five-year study presented at the ASAPS meeting is a multicenter, prospective study of safety and long-term aesthetic results of Aquamid injections for facial soft-tissue augmentation and facial contouring. A total of 116 patients attended the clinics for follow-up five years after their first injection.
According to the trial report, 96 percent of the 116 patients evaluated after five years had “very good” or “good” aesthetic results, and 92 percent said they were “very satisfied” or “satisfied” with the results. The trial’s safety data showed that injection of Aquamid over a five-year period resulted in few adverse events.
Aquamid currently is available in 40 countries and is under clinical investigation in the United States. Data from this trial will support a PMA application with the FDA.
